- Clinical Technology
- Adult Immunization
- Hepatology
- Pediatric Immunization
- Screening
- Psychiatry
- Allergy
- Women's Health
- Cardiology
- Pediatrics
- Dermatology
- Endocrinology
- Pain Management
- Gastroenterology
- Geriatrics
- Infectious Disease
- Obesity Medicine
- Rheumatology
- Oncology
- Nephrology
- Neurology
- Pulmonology
Steroid-Exacerbated Tinea Corporis
A pruritic lesion on the arm of a 26-year-old woman had grown to 22 cm while she was "treating" the eruption with a topical corticosteroid.
A pruritic lesion on the arm of a 26-year-old woman had grown to 22 cm while she was “treating” the eruption with a topical corticosteroid. Joe Monroe, PA-C, of Tulsa, Okla, suspected corticosteroid-exacerbated tinea corporis despite obfuscation of the annular border, which was caused by the lesion's unusually large size.
Tinea corporis was confirmed by a potassium hydroxide evaluation; the patient was advised to discontinue the topical corticosteroid immediately. In addition, a 7-day course of oral terbinafine, 250 mg bid, and application of antifungal cream as needed were prescribed. The dermatophytosis cleared after 1 month.
This patient was an elementary school teacher. It was thought that she acquired the infection from a child in her class.
Lebrikizumab Demonstrates Efficacy, Safety in Patients With Skin of Color With AD
June 11th 2025RAD 2025. Lebrikizumab improved skin clearance, itch, and pigmentation in patients with skin of color and atopic dermatitis, with strong safety data through 24 weeks, according to late-breaking data.
